We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




World’s First AI-Powered Tool to Transform Type 1 Diabetes Diagnosis and Treatment

By LabMedica International staff writers
Posted on 09 Jun 2025

For years, testing for Type 1 Diabetes (T1D) has relied on symptoms and biomarkers that typically become evident only at the disease’s onset, making early detection difficult. More...

This is particularly concerning because early-onset T1D, especially before age 10, tends to be more aggressive and is linked to a reduction in life expectancy of up to 16 years. Accurately forecasting disease progression could allow clinicians to act earlier. Now, an artificial intelligence (AI)-powered tool is showing promise in assessing T1D risk and predicting how patients will respond to treatments, potentially reshaping how the disease is identified and managed.

An international research team led by Western Sydney University (Penrith, NSW, Australia) has created a novel risk score based on microRNAs—tiny RNA molecules found in blood—that can effectively track the evolving risk of developing T1D. These same microRNA markers also predicted early responses to treatments such as islet cell transplantation and the drug imatinib. Published in Nature Medicine, the study evaluated molecular data from 5,983 samples collected from participants in Australia, Canada, Denmark, Hong Kong SAR China, India, New Zealand, and the USA. This led to the development of a Dynamic Risk Score (DRS4C) capable of identifying individuals as either having or not having T1D.

Using AI, the team further refined the risk score, which was validated with data from 662 additional participants. Remarkably, just one hour after therapy, the tool could predict which T1D patients would remain insulin-independent. The same microRNA profile also distinguished between responders and non-responders to the T1D drug therapy before treatment even began. Aside from gauging T1D risk and treatment effectiveness, the risk score may also help differentiate between T1D and Type 2 Diabetes (T2D)—a diagnostic challenge, especially in adults. A sub-analysis highlighted the tool’s potential to classify T2D individuals apart from those with T1D, an area the researchers plan to explore further, as many adult-onset T1D cases are often misdiagnosed as T2D.

“Genetic markers identify lifelong risk, it’s like knowing you live in a flood zone, but dynamic risk scores offer a real-time check on the rising water levels; it reflects current risk rather than a lifelong sentence, allowing for timely and adaptive monitoring without stigma,” said lead researcher Dr. Mugdha Joglekar at the Western Sydney University.


New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
New
Silver Member
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.